Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Intranasal MSCs for Perinatal Arterial Ischemic Stroke
NCT03356821Phase 2Completed
- Start
- Feb 2020
- Primary completion
- Jul 2021
- Modality
- Mesenchymal Stem Cells
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of Provacel in perinatal arterial ischemic stroke (PAIS). Primary endpoint: Number of Participants With Adverse Events Related to Intranasal MSC Treatment (Safety and Tolerability) in the Acute Setting at 24 hours. Started Feb 2020; status: completed.
02
Drugs
Provacel
03
Conditions
perinatal arterial ischemic stroke (PAIS)
Beyond the preview
Go deeper on NCT03356821.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03356821.